Loading…
Pharming Group N.V. is projected to rise to $16.69 by 2027, a +24% move from its current price of $13.41. PHAR is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $13.01 | $13.41 | $13.83 | +0.02% |
| May 30 | $12.85 | $13.41 | $14.01 | +0.04% |
| May 31 | $12.73 | $13.42 | $14.15 | +0.05% |
| Jun 1 | $12.62 | $13.42 | $14.26 | +0.07% |
| Jun 2 | $12.54 | $13.42 | $14.37 | +0.09% |
| Jun 3 | $12.46 | $13.42 | $14.47 | +0.11% |
| Jun 4 | $12.38 | $13.43 | $14.56 | +0.12% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $12.38 | $13.43 | $14.56 | +0.12% |
| Week 2 | $11.99 | $13.44 | $15.07 | +0.25% |
| Week 3 | $11.70 | $13.46 | $15.48 | +0.37% |
| Week 4 | $11.47 | $13.48 | $15.84 | +0.49% |
| Week 5 | $11.26 | $13.49 | $16.16 | +0.62% |
| Week 6 | $11.08 | $13.51 | $16.47 | +0.74% |
| Week 7 | $10.92 | $13.53 | $16.75 | +0.87% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Pharming Group N.V. is a healthcare company in the biopharmaceutical sector that develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema, and Joenja (leniolisib), an oral small molecule PI3K?
inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja and has a development collaboration and license agreement with Novartis. Pharming Group N.V.
was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Pharming Group N.V. trades as PHAR in the healthcare space. The stock is currently priced at $13.62 with a market capitalization of $961.92M and a rank of 2568. The price outlook, shown by year-by-year forecast data, projects a rising trajectory from 2026 onward, with substantial upside potential by 2050.
A major floor 35.8% below — a decisive break under it would weaken the trend.
The nearest floor, 10.5% below — buyers have tended to step in here.
The nearest ceiling, 32.7% above — a clean break opens room to run.
A major ceiling 57.9% above — clearing it would confirm fresh momentum.
Key PHAR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PHAR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $13.06 | Buy | $13.17 | Buy |
| MA 10 | $12.94 | Buy | $13.23 | Buy |
| MA 20 | $13.94 | Sell | $13.86 | Sell |
| MA 50 | $15.54 | Sell | $15.04 | Sell |
| MA 100 | $16.36 | Sell | $15.56 | Sell |
| MA 200 | $15.70 | Sell | $15.01 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.24 | Neutral |
| Stoch RSI (14) | 92.86 | Sell |
| CCI (20) | -23.53 | Neutral |
| Williams %R (14) | -12.96 | Info |
| MACD (12,26,9) | 0.07 | Buy |
| ROC (12) | 3.31 | Buy |
| Bollinger %B (20,2) | 0.42 | Neutral |
| Stochastic %K (14) | 87.04 | Sell |
| TRIX (15) | -0.89 | Sell |
| Awesome (5,34) | -2.19 | Sell |
| Ultimate (7,14,28) | 49.34 | Neutral |
| Momentum (10) | 0.32 | Buy |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 13.26 | Buy |
| ADX (14) | 24.25 | Sell |
| ATR (14) | 0.41 | Info |
The 30-day technical picture shows bullish sentiment, with RSI(14) at 40. The stock trades around key moving averages, with SMA50 at $15.58 and SMA200 at $15.69. On the downside, support is identified at $12.00 and upside resistance at $17.80.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $12.00 | $13.41 | $19.76 | 0% | Neutral | |
| $13.08 | $16.69 | $22.64 | +24% | Bullish | |
| $13.54 | $17.80 | $25.12 | +33% | Bullish | |
| $14.06 | $18.98 | $27.62 | +42% | Bullish | |
| $15.40 | $21.27 | $31.77 | +59% | Bullish | |
| $17.78 | $25.08 | $38.33 | +87% | Bullish | |
| $20.29 | $29.19 | $45.53 | +118% | Bullish | |
| $23.64 | $34.64 | $55.04 | +158% | Bullish | |
| $24.91 | $37.16 | $60.05 | +177% | Bullish | |
| $24.30 | $36.87 | $60.55 | +175% | Bullish | |
| $36.48 | $59.81 | $104.94 | +346% | Bullish | |
| $59.90 | $112.52 | $217.36 | +739% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $12.00 | $13.41 | $15.84 | +0.00% |
| June 2026 | $11.74 | $13.82 | $16.69 | +3.08% |
| July 2026 | $11.46 | $13.63 | $16.70 | -1.42% |
| August 2026 | $11.45 | $13.70 | $16.99 | +0.57% |
| September 2026 | $11.98 | $14.43 | $18.06 | +5.32% |
| October 2026 | $12.29 | $14.88 | $18.78 | +3.12% |
| November 2026 | $12.25 | $14.92 | $18.96 | +0.21% |
| December 2026 | $12.62 | $15.44 | $19.76 | +3.50% |
Click any year to see its month-by-month PHAR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Pharming Group N.V.'s 2026 outlook centres on $13.41, within a $12.00 to $19.76 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, PHAR could reach as high as $22.64, with a base case around $16.69 and support toward $13.08 — roughly +24% from $13.41. Buyers look set to stay in control over this stretch.
Expect PHAR to range from $13.54 to $25.12 through 2028. The $17.80 average target implies a +33% move from current prices. That is up +7% on the projected 2027 average. Momentum favours further upside here.
The PHAR price prediction for 2029 points to an average of $18.98 (low $14.06, high $27.62) — a potential gain of +42% on today's $13.41. Buyers look set to stay in control over this stretch.
In 2030, PHAR is projected to trade between $15.40 and $31.77, averaging $21.27 — a potential gain of +59% from today's $13.41. That is up +12% on the projected 2029 average. Momentum favours further upside here.
Pharming Group N.V.'s 2031 outlook centres on $25.08, within a $17.78 to $38.33 range. That is up +18% on the projected 2030 average. That marks a +87% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, PHAR could reach as high as $45.53, with a base case around $29.19 and support toward $20.29 — roughly +118% from $13.41. Momentum favours further upside here.
Expect PHAR to range from $23.64 to $55.04 through 2033. The $34.64 average target implies a +158% move from current prices. That is up +19% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The PHAR price prediction for 2034 points to an average of $37.16 (low $24.91, high $60.05) — a potential gain of +177% on today's $13.41. Momentum favours further upside here.
In 2035, PHAR is projected to trade between $24.30 and $60.55, averaging $36.87 — a potential gain of +175% from today's $13.41. That is -1% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
Pharming Group N.V.'s 2040 outlook centres on $59.81, within a $36.48 to $104.94 range. That is up +62% on the projected 2035 average. That marks a +346% change versus current levels. Momentum favours further upside here.
By 2050, PHAR could reach as high as $217.36, with a base case around $112.52 and support toward $59.90 — roughly +739% from $13.41. Buyers look set to stay in control over this stretch.
Investing $1,000 in PHAR today (≈ 74.571216 PHAR) could be worth
$8,390.56
+$7,390.56 (+739%) by 2050 · US Dollar
Based on the average projected PHAR price of $112.52 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PHARwould be worth at today's price.
$1,000 invested in PHAR on May 27, 2025 (≈ 92.592591 PHAR) would be worth
$1,241.67
+$241.67 (+24.2%) today · 1.24× · US Dollar
Based on a PHAR entry price of $10.8 vs. today's $13.41.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $12.87 | $1,041.96 | +4.2% |
| 1 month ago | $16.92 | $792.55 | -20.7% |
| 3 months ago | $16.37 | $819.18 | -18.1% |
| 6 months ago | $17.5 | $766.29 | -23.4% |
| 1 year ago | $10.8 | $1,241.67 | +24.2% |
| All time (5.0y) ago | $12.28 | $1,091.75 | +9.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PHAR forecast.
Our base-case forecast reaches $27.00 around 2032.
Implied market cap at $27.00: $1.91B
Longer-term forecasts imply a rising path for Pharming Group N.V. The 2026 forecast lists an avg price of $13.62 with a min of $12.00 and a max of $20.16, and a neutral sentiment. From 2027 onward, the outlook turns bullish with progressively higher averages: 2027 avg $16.89, 2028 avg $17.94, 2029 avg $19.12, 2030 avg $21.32, 2031 avg $25.10, 2032 avg $29.27, 2033 avg $34.73, 2034 avg $37.19, 2035 avg $36.82, 2040 avg $59.49, and 2050 avg $111.59.
Max values rise to $32.03 (2030), $105.26 (2040), and $217.71 (2050). Corresponding ROI figures are 0% (2026), 24% (2027), 31.7% (2028), 40.4% (2029), 56.5% (2030), 84.3% (2031), 114.9% (2032), 155% (2033), 173% (2034), 170.3% (2035), 336.8% (2040), and 719.3% (2050). The sentiment remains BULLISH from 2027 through 2050, reflecting an ongoing favorable long-term trajectory, though these are estimates and not guarantees, with risk inherent in any forecast.
Tap a question to reveal the answer.
In 2030 the forecast shows an avg price of $21.32 with a min of $15.36 and a max of $32.03, representing an ROI of 56.5% and a bullish outlook.
The forecast indicates a neutral stance in 2026 but a bullish path from 2027 onward, with rising average prices and positive ROI through 2050. The long-run outlook shows substantial upside, albeit with uncertainty inherent in any forecast.
Yes. The forecast max values exceed $50: $60.91 in 2035, $105.26 in 2040, and $217.71 in 2050, indicating that $50 could be cited within the forecast horizon.
The 2026 forecast lists a 2026 avg of $13.62, with a min of $12.00 and a max of $20.16, and an ROI of 0%. Sentiment is Neutral.
For 2040 the forecast shows a avg of $59.49, a min of $35.89, and a max of $105.26, with an ROI of 336.8% and a bullish sentiment.
Pharming Group N.V. Community Discussion
0Share your Pharming Group N.V. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.